ZA201204365B - Darunavir polymorph and process for preparation thereof - Google Patents

Darunavir polymorph and process for preparation thereof

Info

Publication number
ZA201204365B
ZA201204365B ZA2012/04365A ZA201204365A ZA201204365B ZA 201204365 B ZA201204365 B ZA 201204365B ZA 2012/04365 A ZA2012/04365 A ZA 2012/04365A ZA 201204365 A ZA201204365 A ZA 201204365A ZA 201204365 B ZA201204365 B ZA 201204365B
Authority
ZA
South Africa
Prior art keywords
darunavir
polymorph
preparation
darunavir polymorph
Prior art date
Application number
ZA2012/04365A
Other languages
English (en)
Inventor
Manjinder Singh Phull
Dharmaraj Ramachandra Rao
Rajendra Narayanrao Kankan
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of ZA201204365B publication Critical patent/ZA201204365B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2012/04365A 2010-01-05 2012-06-14 Darunavir polymorph and process for preparation thereof ZA201204365B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN33MU2010 2010-01-05

Publications (1)

Publication Number Publication Date
ZA201204365B true ZA201204365B (en) 2013-12-23

Family

ID=43125640

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/04365A ZA201204365B (en) 2010-01-05 2012-06-14 Darunavir polymorph and process for preparation thereof

Country Status (9)

Country Link
US (2) US20130029945A1 (enExample)
EP (1) EP2521728B1 (enExample)
JP (2) JP2013516397A (enExample)
KR (1) KR20120123077A (enExample)
AU (1) AU2010340799B2 (enExample)
CA (1) CA2785998A1 (enExample)
NZ (1) NZ600994A (enExample)
WO (1) WO2011083287A2 (enExample)
ZA (1) ZA201204365B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700645B2 (en) 2002-05-16 2010-04-20 Tibotec Pharmaceuticals Ltd. Pseudopolymorphic forms of a HIV protease inhibitor
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
PL2528923T3 (pl) 2010-01-28 2015-01-30 Mapi Pharma Ltd Sposób wytwarzania darunawiru i pochodnych darunawiru
US9216990B2 (en) * 2011-12-05 2015-12-22 Mylan Labs Limited Crystalline Darunavir
CN103509031B (zh) * 2012-06-20 2016-04-27 上海迪赛诺药业有限公司 制备达芦那韦无定形物的方法
EP3795572B1 (en) 2012-07-24 2023-11-15 Laurus Labs Limited Darunavir propionate solvate
WO2016092525A1 (en) 2014-12-12 2016-06-16 Lupin Limited Darunavir n-propanol solvate and process for preparation thereof
CN106854212A (zh) * 2015-12-08 2017-06-16 浙江九洲药业股份有限公司 一种达芦那韦无定型的制备方法
CN106242307A (zh) * 2016-08-11 2016-12-21 京东方科技集团股份有限公司 用于强化制品的边缘的方法、玻璃及显示装置
EP3532478B1 (en) * 2016-10-27 2021-05-26 Gilead Sciences, Inc. Crystalline form of darunavir free base
CN108727401A (zh) * 2017-04-20 2018-11-02 盐城迪赛诺制药有限公司 达鲁那韦新晶型及其制备方法和应用
CN108794498A (zh) * 2017-05-03 2018-11-13 江苏瑞科医药科技有限公司 一种达芦那韦无定型的制备方法
CN109053753A (zh) * 2018-08-05 2018-12-21 浙江大学 一种制备达卢那韦二水合物晶型的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2127938T3 (es) 1993-08-24 1999-05-01 Searle & Co Hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas.
PT2336134T (pt) 1998-06-23 2016-10-19 The Board Of Trustees Of The Univ Of Illionis Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
US7700645B2 (en) * 2002-05-16 2010-04-20 Tibotec Pharmaceuticals Ltd. Pseudopolymorphic forms of a HIV protease inhibitor
KR101192859B1 (ko) 2003-12-23 2012-10-19 얀센 알 앤드 디 아일랜드 (3r,3as,6ar)-헥사하이드로푸로〔2,3-b〕푸란-3-일(1s,2r)-3-〔〔(4-아미노페닐)설포닐〕(이소부틸)아미노〕-1-벤질-2-하이드록시프로필카바메이트의 제조방법
CA2776807C (en) * 2009-09-17 2018-10-16 Mylan Laboratories Limited An improved process for the preparation of darunavir
WO2011073993A1 (en) * 2009-12-16 2011-06-23 Hetero Research Foundation Polymorphs of darunavir

Also Published As

Publication number Publication date
WO2011083287A2 (en) 2011-07-14
JP2013516397A (ja) 2013-05-13
CA2785998A1 (en) 2011-07-14
JP2016028085A (ja) 2016-02-25
AU2010340799A1 (en) 2012-07-05
WO2011083287A3 (en) 2011-09-15
EP2521728B1 (en) 2016-09-07
NZ600994A (en) 2014-04-30
US20130029945A1 (en) 2013-01-31
US20150141383A1 (en) 2015-05-21
EP2521728A2 (en) 2012-11-14
AU2010340799B2 (en) 2015-06-11
KR20120123077A (ko) 2012-11-07

Similar Documents

Publication Publication Date Title
EP2609120A4 (en) IMPROVED PROCESS FOR PREPARING SUGAMMADEX
ZA201202504B (en) Process for the preparation of calcobutrol
PL2632889T3 (pl) Związki pośrednie i sposób wytwarzania fingolimodu
AP3222A (en) Germination-stimulant carbamate derivatives and process for preparation thereof
PT2710015T (pt) Polimorfo de rifaximina e processo para a sua preparação
ZA201300776B (en) Improved process for the preparation of febuxostat
IL220477A (en) A process for making Darunavir and intermediates of Daronavir
IL225754A0 (en) Processes for the preparation of lubiprostone
ZA201206221B (en) Process for the preparation of nebivolol
IL226153A0 (en) Process for preparing nabivolol
EP2596007A4 (en) PROCESS FOR THE PREPARATION OF 17-DEOXY-CORTICOSTEROIDS
ZA201300546B (en) Process for the preparation of 3-haloalkylpyrazoles
PT2603319E (pt) Processo para a preparação de uretanos
PT2390246T (pt) Processo para a preparação de aminaftona
PL389013A1 (pl) Nowe winylo-alkinylopodstawione związki germanu oraz sposób otrzymywania winylo-alkinylopodstawionych związków germanu
EP2537851A4 (en) PROCESS FOR PREPARING B-GLYCOSIDE COMPOUNDS
ZA201108148B (en) Triazine-aryl-bis-indoles and process for preparation thereof
PL2598504T3 (pl) Sposób otrzymywania dimiracetamu
GB201301307D0 (en) Crystalline form of prulifloxacin and processes for its preparation
PL391702A1 (pl) Sposób otrzymywania 5-hydroksykreatyniny i N-metyloguanidyny
IL224304A (en) A process for making dichlorobulben
IL226042A0 (en) Intermediates and methods for preparing fingolimod
PL392488A1 (pl) Sposób jednoczesnego wytwarzania 3ß,7α-dihydroksyandrost-5-en-17-onu i 3ß,7ß-dihydroksyandrost-5-en-17-onu
PL391303A1 (pl) Nowa pochodna pirymidopirymidyny i sposób wytwarzania nowej pochodnej pirymidopirymidyny
PL391316A1 (pl) Nowa pochodna pirymidopirymidyny i sposób wytwarzania nowej pochodnej pirymidopirymidyny